An observational study in Sickle Cell Disease, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-04-27.
Sponsored by Novartis Pharmaceuticals · Observational
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
1,103 studies on the registry are indexed under Anemia, Sickle Cell; 235 are open to participants now.
This study's enrollment of 297 is above the median of 100 across 287 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
This was a retrospective, noninterventional cohort study
Exclusion criteria:
None specified
Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab
Time frame: Up to 12 months
Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab
Time frame: Up to 12 months
Number of patients who discontinued treatment with crizanlizumab
Time frame: Up to 24 months
Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab
Time frame: Up to 24 months
Reasons for early discontinuation of crizanlizumab treatment
Time frame: Up to 24 months
Number of sickle cell disease (SCD)-related hospitalizations
Time frame: Up to 24 months
Number of SCD-related emergency department (ED) visits
Time frame: Up to 24 months
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals